(R)-(-)-RolipramCAS# 85416-75-7 |
- Salmefamol
Catalog No.:BCC1919
CAS No.:18910-65-1
- Guanfacine hydrochloride
Catalog No.:BCC1609
CAS No.:29110-48-3
- Doxazosin Mesylate
Catalog No.:BCC1257
CAS No.:77883-43-3
- Medetomidine
Catalog No.:BCC1736
CAS No.:86347-14-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 85416-75-7 | SDF | Download SDF |
PubChem ID | 448055 | Appearance | Powder |
Formula | C16H21NO3 | M.Wt | 275.34 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | (-)-ROLIPRAM | ||
Solubility | DMSO : ≥ 49 mg/mL (177.96 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | (4R)-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one | ||
SMILES | COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3 | ||
Standard InChIKey | HJORMJIFDVBMOB-LBPRGKRZSA-N | ||
Standard InChI | InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)/t12-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | More active enantiomer of the PDE4 inhibitor rolipram; 2-10-fold more potent than the S-(+) enantiomer. Also available as part of the Phosphodiesterase Inhibitor. |
(R)-(-)-Rolipram Dilution Calculator
(R)-(-)-Rolipram Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.6319 mL | 18.1594 mL | 36.3187 mL | 72.6375 mL | 90.7968 mL |
5 mM | 0.7264 mL | 3.6319 mL | 7.2637 mL | 14.5275 mL | 18.1594 mL |
10 mM | 0.3632 mL | 1.8159 mL | 3.6319 mL | 7.2637 mL | 9.0797 mL |
50 mM | 0.0726 mL | 0.3632 mL | 0.7264 mL | 1.4527 mL | 1.8159 mL |
100 mM | 0.0363 mL | 0.1816 mL | 0.3632 mL | 0.7264 mL | 0.908 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- S- (+)-Rolipram
Catalog No.:BCC2303
CAS No.:85416-73-5
- Rilmenidine Phosphate
Catalog No.:BCC5637
CAS No.:85409-38-7
- Ropivacaine mesylate
Catalog No.:BCC9137
CAS No.:854056-07-8
- (-)-Haplomyrfolin
Catalog No.:BCN3225
CAS No.:85404-48-4
- Norcaesalpinin E
Catalog No.:BCN7006
CAS No.:854038-96-3
- Dasatinib hydrochloride
Catalog No.:BCC1517
CAS No.:854001-07-3
- OGT 2115
Catalog No.:BCC7458
CAS No.:853929-59-6
- NVP-BAG956
Catalog No.:BCC1813
CAS No.:853910-02-8
- (+)-AJ 76 hydrochloride
Catalog No.:BCC6747
CAS No.:85378-82-1
- SKF 89976A hydrochloride
Catalog No.:BCC6930
CAS No.:85375-15-1
- 5,19-Epoxy-19R,25-dimethoxycucurbita-6,23-dien-3-ol
Catalog No.:BCN1328
CAS No.:85372-72-1
- 5,19-Epoxy-19S,25-dimethoxycucurbita-6,23-dien-3-ol
Catalog No.:BCN1329
CAS No.:85372-70-9
- Caffeic anhydride
Catalog No.:BCN3295
CAS No.:854237-32-4
- Ajugamarin chlorohydrin
Catalog No.:BCN3664
CAS No.:85447-27-4
- 4-Chlorotestosterone acetate
Catalog No.:BCC8705
CAS No.:855-19-6
- Eupatorin
Catalog No.:BCN4405
CAS No.:855-96-9
- PK 11195
Catalog No.:BCC6745
CAS No.:85532-75-8
- Safflor Yellow A
Catalog No.:BCN2408
CAS No.:85532-77-0
- NBI-74330
Catalog No.:BCC4111
CAS No.:855527-92-3
- Rhodionin
Catalog No.:BCN1248
CAS No.:85571-15-9
- Kurarinol
Catalog No.:BCN3447
CAS No.:855746-98-4
- Zaltidine
Catalog No.:BCC2068
CAS No.:85604-00-8
- Gynuramine
Catalog No.:BCN2085
CAS No.:85611-43-4
- (2-Aminoethyl)phosphinic acid
Catalog No.:BCN1761
CAS No.:85618-16-2
Regio- and enantioselective palladium-catalyzed allylic alkylation of nitromethane with monosubstituted allyl substrates: synthesis of (R)-rolipram and (R)-baclofen.[Pubmed:22992268]
J Org Chem. 2012 Oct 19;77(20):8980-5.
The Pd-catalyzed asymmetric allylic alkylation (AAA) reaction of nitromethane with monosubstituted allyl substrates was realized for the first time to provide corresponding products in high yields with excellent regio- and enantioselectivities. The protocol was applied to the enantioselective synthesis of (R)-baclofen and (R)-rolipram.
Voxelwise quantification of [(11)C](R)-rolipram PET data: a comparison between model-based and data-driven methods.[Pubmed:23512132]
J Cereb Blood Flow Metab. 2013 Jul;33(7):1032-40.
This study compared model-based and data-driven methods to assess the best methodology for generating precise and accurate parametric maps of the parameters of interest in [(11)C](R)-rolipram brain positron-emission tomography studies. Parametric images were generated using (1) a two-tissue compartmental model (2TCM) solved with the hierarchical basis function method (H-BFM) linear estimator; (2) data-driven spectral-based methods: standard spectral analysis (std SA) and rank-shaping SA (RS); and (3) the Logan graphical plot. Nonphysiologic VT estimates were eliminated and the remaining ones were compared with the reference values, i.e., those obtained with a voxelwise 2TCM solved with a nonlinear estimator. With regard to voxelwise VT estimates, H-BFM showed the best agreement with weighted nonlinear least square (WNLLS) values and the lowest percentage of mean relative difference (1+/-1%). All methods showed comparable variability in the relative differences. H-BFM provided the best correlation with WNLLS (y=1.034x-0.013; R(2)=0.973). Despite a slight bias, the other three methods also showed good agreement and high correlation (R(2)>0.96). H-BFM yielded the most reliable voxelwise quantification of [(11)C](R)-rolipram as well as the complete description of the tracer kinetic. The Logan plot represents a valid alternative if only VT estimation is required. Its marginally higher bias was outweighed by a low computational time, ease of implementation, and robustness.
Multistep continuous-flow synthesis of (R)- and (S)-rolipram using heterogeneous catalysts.[Pubmed:25877201]
Nature. 2015 Apr 16;520(7547):329-32.
Chemical manufacturing is conducted using either batch systems or continuous-flow systems. Flow systems have several advantages over batch systems, particularly in terms of productivity, heat and mixing efficiency, safety, and reproducibility. However, for over half a century, pharmaceutical manufacturing has used batch systems because the synthesis of complex molecules such as drugs has been difficult to achieve with continuous-flow systems. Here we describe the continuous-flow synthesis of drugs using only columns packed with heterogeneous catalysts. Commercially available starting materials were successively passed through four columns containing achiral and chiral heterogeneous catalysts to produce (R)-rolipram, an anti-inflammatory drug and one of the family of gamma-aminobutyric acid (GABA) derivatives. In addition, simply by replacing a column packed with a chiral heterogeneous catalyst with another column packed with the opposing enantiomer, we obtained antipole (S)-rolipram. Similarly, we also synthesized (R)-phenibut, another drug belonging to the GABA family. These flow systems are simple and stable with no leaching of metal catalysts. Our results demonstrate that multistep (eight steps in this case) chemical transformations for drug synthesis can proceed smoothly under flow conditions using only heterogeneous catalysts, without the isolation of any intermediates and without the separation of any catalysts, co-products, by-products, and excess reagents. We anticipate that such syntheses will be useful in pharmaceutical manufacturing.
Image-derived input function derived from a supervised clustering algorithm: methodology and validation in a clinical protocol using [11C](R)-rolipram.[Pubmed:24586526]
PLoS One. 2014 Feb 20;9(2):e89101.
Image-derived input function (IDIF) obtained by manually drawing carotid arteries (manual-IDIF) can be reliably used in [(11)C](R)-rolipram positron emission tomography (PET) scans. However, manual-IDIF is time consuming and subject to inter- and intra-operator variability. To overcome this limitation, we developed a fully automated technique for deriving IDIF with a supervised clustering algorithm (SVCA). To validate this technique, 25 healthy controls and 26 patients with moderate to severe major depressive disorder (MDD) underwent T1-weighted brain magnetic resonance imaging (MRI) and a 90-minute [(11)C](R)-rolipram PET scan. For each subject, metabolite-corrected input function was measured from the radial artery. SVCA templates were obtained from 10 additional healthy subjects who underwent the same MRI and PET procedures. Cluster-IDIF was obtained as follows: 1) template mask images were created for carotid and surrounding tissue; 2) parametric image of weights for blood were created using SVCA; 3) mask images to the individual PET image were inversely normalized; 4) carotid and surrounding tissue time activity curves (TACs) were obtained from weighted and unweighted averages of each voxel activity in each mask, respectively; 5) partial volume effects and radiometabolites were corrected using individual arterial data at four points. Logan-distribution volume (V T/f P) values obtained by cluster-IDIF were similar to reference results obtained using arterial data, as well as those obtained using manual-IDIF; 39 of 51 subjects had a V T/f P error of <5%, and only one had error >10%. With automatic voxel selection, cluster-IDIF curves were less noisy than manual-IDIF and free of operator-related variability. Cluster-IDIF showed widespread decrease of about 20% [(11)C](R)-rolipram binding in the MDD group. Taken together, the results suggest that cluster-IDIF is a good alternative to full arterial input function for estimating Logan-V T/f P in [(11)C](R)-rolipram PET clinical scans. This technique enables fully automated extraction of IDIF and can be applied to other radiotracers with similar kinetics.
Inhibitory effects of rolipram on partially purified phosphodiesterase 4 from rat brains.[Pubmed:9681571]
Jpn J Pharmacol. 1998 Jun;77(2):147-54.
Several previous studies have demonstrated that the phosphodiesterase 4 selective inhibitor rolipram affects cellular function at a much lower concentration than the reported Ki value for phosphodiesterase 4 inhibition. In this study, we examined the inhibitory effect of rolipram on rat brain phosphodiesterase 4 to determine the heterogeneity of the enzyme activity. Partial purification of various phosphodiesterases from the rat brain was performed by anion-exchange chromatography. The eluant was pooled into four fractions, two of which manifested cAMP-selective phosphodiesterase activity that was blocked by 10 microM of rolipram, indicating the presence of phosphodiesterase 4 in these fractions. The IC50 of rolipram (racemate) of these two fractions was 492 and 79 nM, respectively. The R-(-)-enantiomer of rolipram inhibited the cAMP-phosphodiesterase activity in the latter fraction 10 times more than did S-(+)-rolipram, and the inhibition of the former fraction was less stereospecific. Dixon plot analysis revealed that the rolipram enantiomers inhibited the cAMP-phosphodiesterase in the latter fraction in a multiphasic manner, with two Ki values, one at the micromolar level and the other at the sub-micromolar level, respectively, for both of the enantiomers. These results suggest that there is a heterogeneity for phosphodiesterase 4 in the rat brain, and some of the phosphodiesterase forms are sensitive to rolipram.
Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells.[Pubmed:9337850]
Biochem J. 1997 Aug 15;326 ( Pt 1):53-60.
The type 4 phosphodiesterase (PDE) family comprises four enzymes (4A, 4B, 4C and 4D) that are characterized by their specificity for cAMP and selective inhibition by the anti-depressant drug rolipram (4-[3-(cyclopentoxyl)-4-methoxyphenyl]2-pyrrolidone). In common with other PDEs, they consist of a central conserved domain associated with catalytic activity in addition to two N-terminal upstream conserved regions (UCR1 and UCR2) that are unique to the type 4 enzymes. We have isolated a 2 kb cDNA encoding a full-length type 4A PDE{HSPDE4A4B[Bolger, Michaeli, Martins, St.John, Steiner, Rodgers, Riggs, Wigler and Ferguson (1993) Mol. Cell. Biol. 13, 6558-6571]} from a human frontal cortex cDNA library. Northern blot analysis showed that the major PDE4A mRNA of 4.5 kb was widely distributed in different human tissues. The recombinant PDE4A expressed in COS cells had a molecular mass of approx. 117 kDa as revealed by SDS/PAGE/Western blotting with a PDE4A-specific antibody and was specific for cAMP with a Km of 4.8 microM. The enzyme activity was potently inhibited by R-rolipram (IC50 204 nM) and showed a 2.7-fold stereoselectivity over the S enantiomer. Analysis of the kinetics of inhibition indicated that R-rolipram did not behave as a simple competitive inhibitor. Dixon replots suggested that there was more than one mode of interaction consistent with the detection in the enzyme of a high-affinity binding site for R-rolipram with a Kd of 2.3 nM. Truncation of the PDE4A enzyme by deletion mutagenesis showed that neither of the UCRs was required for catalytic activity and identified an approx. 71 kDa core enzyme with a K(m) for cAMP of 3.3 microM. In contrast with the full-length PDE4A, R-rolipram behaved as a simple competitive inhibitor of this form of the enzyme with decreased potency (IC50 1022 nM) and no stereoselectivity. In addition, no high-affinity rolipram-binding site was detected in the truncated enzyme, indicating that this interaction involves sequences upstream of the catalytic domain of the enzyme.
Stereospecific binding of the antidepressant rolipram to brain protein structures.[Pubmed:3019721]
Eur J Pharmacol. 1986 Aug 7;127(1-2):105-15.
The characteristics for the binding of the selective cAMP phosphodiesterase inhibitor and antidepressant agent rolipram to brain and peripheral organs were investigated. (+/-)-[3H]Rolipram equilibrium binding and Scatchard analysis revealed saturable, reversible, stereospecific, Mg2+-dependent and heat-sensitive binding with an apparent Hill number of 1. Binding was detected both to membrane-bound and soluble sites, with dissociation constants Kd of 1.2 and 2.4 nM, respectively, and binding site concentrations (Bmax) of 19.3 and 23.6 pmol/g rat forebrain. The (-)-enantiomer of rolipram was ca. 20 times more effective than the (+)-enantiomer in displacing (+/-)-[3H]rolipram from membranes. Rolipram bound to brain tissue of all mammalian species tested including man, while tissue from bird and fish showed less binding. Organs other than brain exhibited only negligible binding. Only specific cAMP phosphodiesterase inhibitors (ICI 63.197, Ro 20-1724) were potent competitors, while rolipram itself was inactive in a variety of receptor binding assays of neuroactive ligands. The kinetics of (-)-[3H]rolipram binding to the particulate fraction revealed a complex association and dissociation behaviour. The nature of the rolipram binding protein(s) is not clear, but the low affinity binding site evident from binding kinetics may represent a rolipram-sensitive phosphodiesterase isoenzyme also common to some peripheral organs, while the high affinity binding site(s) may be related to PDE isoenzymes more confined to the central nervous system.